Metronomic treatment of vinorelbine with oral capecitabine is tolerable in the randomized Phase 2 study XeNa including patients with HER2 non-amplified metastatic breast cancer.
Breast cancer
metronomic treatment
randomized trial
Journal
Acta oncologica (Stockholm, Sweden)
ISSN: 1651-226X
Titre abrégé: Acta Oncol
Pays: England
ID NLM: 8709065
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
pubmed:
2
12
2020
medline:
19
8
2021
entrez:
1
12
2020
Statut:
ppublish
Résumé
Metronomic treatment is hypothesized to be less toxic and more effective as compared to standard maximal tolerable dosing treatment in metastatic cancer disease. We tested the metronomic treatment principle with vinorelbine in a randomized phase 2 setting combined with standard capecitabine treatment in the XeNa trial with Clinical Trials.gov identifier number: NCT0141771. 120 patients with disseminated HER2 non-amplified breast cancer were included. Randomization was between Arm A: vinorelbine 60 mg/m The treatment was generally well-tolerated. The response rate (RR) was 24% (arm A) We confirmed that the combination of vinorelbine and capecitabine was well tolerated. Metronomic treatment can be used with acceptable adverse events (AEs), but we did not find significant difference in the effect compared to the standard treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Metronomic treatment is hypothesized to be less toxic and more effective as compared to standard maximal tolerable dosing treatment in metastatic cancer disease.
MATERIAL AND METHODS
METHODS
We tested the metronomic treatment principle with vinorelbine in a randomized phase 2 setting combined with standard capecitabine treatment in the XeNa trial with Clinical Trials.gov identifier number: NCT0141771. 120 patients with disseminated HER2 non-amplified breast cancer were included. Randomization was between Arm A: vinorelbine 60 mg/m
RESULTS
RESULTS
The treatment was generally well-tolerated. The response rate (RR) was 24% (arm A)
CONCLUSIONS
CONCLUSIONS
We confirmed that the combination of vinorelbine and capecitabine was well tolerated. Metronomic treatment can be used with acceptable adverse events (AEs), but we did not find significant difference in the effect compared to the standard treatment.
Identifiants
pubmed: 33259244
doi: 10.1080/0284186X.2020.1851045
doi:
Substances chimiques
Vinblastine
5V9KLZ54CY
Capecitabine
6804DJ8Z9U
Receptor, ErbB-2
EC 2.7.10.1
Vinorelbine
Q6C979R91Y
Types de publication
Clinical Trial, Phase II
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM